San Jose, California (PRWEB) August 29, 2011

New drug discovery is increasingly becoming a high cost proposition for pharmaceutical and biotech companies, owing particularly to the high attrition rate due to drug failure at different stages. Development of a new drug costs about $ 1.0 billion and takes, on an average, 7-10 years before reaching commercialization stage. With companies facing major revenue losses owing to patent expirations and demanding regulatory requirements, besides growing cost pressures, there is growing need to reduce fixed costs and adopt flexible cost models. ADME-Tox issues comprise a leading cause for drug failure/attrition during the pre-clinical as well as clinical stage. The increasing number of drug targets and volume of assay points in drug discovery process are necessitating the need for identifying and eliminating potential hits with high ADME and toxicity profiles. Hence ADME/Tox screening has now become essential at early stage drug discovery and development process. In addition, rising drug discovery costs are fostering the adoption of extensive ADME-Tox screenings not only at early stage of drug discovery and development process but also through the entire process.

Pharma companies are focusing efforts on various innovative approaches to enhance and accelerate ADME-Tox assessments. In silico predictive ADME-Tox is growing at a fast clip and is expected to gain further momentum as the technology can drastically reduce the expenditure incurred due to late stage failure of drug compounds owing to poor ADME-Tox properties. The use of computational models in prediction of ADME/Toxicity properties of compounds is also increasing at a rapid rate owing to the fact that these models offer significant benefits in high throughput screening (HTS). Owing to the significant role of transporter proteins, analysis of drug transporters is gradually becoming a part of ADME assessment and is likely to become a part of regulatory standard for new drug applications.

The United States and Europe account for a lion?s share of the global ADME-Toxicology testing market, as stated by the new market research report on ADME-Toxicology Testing. With the US being home to most of the global pharmaceutical giants, the nation corners a major share of new drug discoveries across the world. The US market for In-Vivo Toxicology testing is forecast to exceed US$ 1.0 billion by 2015. Cell-based assays are expected to emerge as a vital technology in in-vitro test methods in toxicity testing, given their role either as a part of a tiered testing scheme or as test batteries in predicting human toxicity endpoints. Growing interest in screening new drug candidates has propelled the manufacturers of cell-based assays to provide reliable and robust solutions for drug discovery. High Throughput/High Content (HTS/HCS) cell-based assays enable the evaluation of several toxicity endpoints, which is expected to enable identification of various aspects associated with the onset of cell stress. This, in turn, aids in predicting specific cytotoxic effects.

While the US is expected to continue its dominant position in global market, developing regions including Asia-Pacific are poised to register the fastest growth. The high growth in these markets is buoyed by government support and increasing number of collaborations between foreign pharma companies and research laboratories in the region. In particular, India and China have rapidly emerged as ?hot spot? for R&D investment. The emergence and success of contract research organizations (CROs) has made outsourcing of various research projects related to new drug development a viable alternative for pharmaceutical companies, particularly for mid-tier and small players with inadequate infrastructure. Increasing emphasis on early stage ADME-Tox screening and prediction during the last decade and a half has resulted in emergence of large number of dedicated ADME-Tox CROs.

ADME-Tox technologies market place includes pharmaceutical and biotech companies with their in-house research teams and contract research organizations (CROs) that provide ADME-Tox screening at contract. Select players profiled in the report include Accelrys, Inc., ACEA Biosciences, Inc., Agilent Technologies, Inc., Albany Molecular Research, Inc., BD Biosciences, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Caliper Life Sciences, Inc., Cambridge Cell Networks Ltd, CeeTox, Inc., Cellartis AB, Celsis International Ltd., Cyprotex PLC, Entelos, Inc., Life Technologies Corporation, Molecular Discovery Ltd., MultiCASE, Inc., Noray Bioinformatics S.L., Optivia Biotechnology, Inc., Promega Corporation, Taconic Farms, Inc., Thermo Fisher Scientific, Inc., Xceleron, Inc. among others.

The research report titled ?ADME-Toxicology Testing: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a strategic review of the drug discovery and development market, key market trends in ADME-Tox Technologies, recent product launches, strategic corporate initiatives, and profiles of key market participants. The report provides annual expenditure on ADME-Tox Technologies by the following geographic markets – US, Canada, Japan, Europe and Rest of World. Segments analyzed include Toxicology (In-Vivo and In-Vitro) and ADME.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/ADME_Toxicology_Testing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###